NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Start Date
5/8/2025
Completion Date
10/1/2027
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Eligibility Criteria
Age Range: 18 years to 65 years
Interventions
NBI-1117568
Placebo
Conditions
Locations
Neurocrine Clinical Site
Bryant, Arkansas 72022
United States
Neurocrine Clinical Site
Little Rock, Arkansas 72211
United States
Neurocrine Clinical Site
Anaheim, California 92805
United States
Neurocrine Clinical Site
Pico Rivera, California 90660
United States
Neurocrine Clinical Site
San Diego, California 92123
United States
Neurocrine Clinical Site
Sherman Oaks, California 91403
United States
Neurocrine Clinical Site
Torrance, California 90504
United States
Neurocrine Clinical Site
Hollywood, Florida 33024
United States
Neurocrine Clinical Site
Miami Lakes, Florida 33016
United States
Neurocrine Clinical Site
Atlanta, Georgia 30331
United States
Neurocrine Clinical Site
Decatur, Georgia 30030
United States
Neurocrine Clinical Site
Snellville, Georgia 30078
United States
Neurocrine Clinical Site
Chicago, Illinois 60640
United States
Neurocrine Clinical Site
Gaithersburg, Maryland 20877
United States
Neurocrine Clinical Site
Watertown, Massachusetts 02472
United States
Neurocrine Clinical Site
Marlton, New Jersey 08053
United States
Neurocrine Clinical Site
Staten Island, New York 10314
United States
Neurocrine Clinical Site
The Bronx, New York 10461
United States
Neurocrine Clinical Site
Austin, Texas 78754
United States
Neurocrine Clinical Site
DeSoto, Texas 75115
United States
Neurocrine Clinical Site
Houston, Texas 77043
United States